FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a pharmaceutical composition based on a compound of formula 
(I) or its pharmaceutically acceptable salt or solvate. wherein X is S or O, and provided X is S, R1 is OH or NH2; and provided X is O, R1 is OH, NH2 or NHMe. The invention also refers to a compound of formula (I) and a based kit.
EFFECT: there are prepared new imidazolidine derivatives effective in treating prostate cancer.
28 cl, 14 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICALLY ACTIVE COMPOUNDS | 2013 |
|
RU2654942C2 |
| H4 ANTAGONIST COMPOUNDS | 2021 |
|
RU2837355C1 |
| SPIRO OXINDOLE MDM2 ANTAGONISTS | 2010 |
|
RU2553269C2 |
| HIGHLY ACTIVE MATERIAL CONSTITUTING A MIXED OXIDE OF TRANSITION METALS, HIGHLY ACTIVE QUATERNARY METAL MATERIALS USING COMPOUNDS OF SHORT-CHAIN QUATERNARY ALKYL AMMONIUM | 2018 |
|
RU2757295C1 |
| INDAZOLE-CARBOXAMIDE COMPOUNDS | 2005 |
|
RU2404179C2 |
| FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | 2016 |
|
RU2740187C2 |
| ELECTROLUMINESCENT DEVICE | 2006 |
|
RU2413335C2 |
| 4-HYDROXYBENZOMORPHAN | 2005 |
|
RU2480455C2 |
| ANTIBODY DRUG CONJUGATES | 2014 |
|
RU2669812C2 |
| DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
